enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference

Executives from enGene (NASDAQ: ENGN) provided an update on the company's detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory interactions, and commercial planning as the study advances. Protocol amendments and response-rate improvement In discussing modifications to the NMIBC trial protocol, the company highlighted three changes: T1 re-resection, TA reinduction, and a